Journal Articles Piezoelectric Nanogenerators

journal articlespiezoelectric nanogenerators represents a topic that has garnered significant attention and interest. The New England Journal of Medicine | Research & Review Articles on .... The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ... Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...

Current Issue | New England Journal of Medicine. Additionally, explore the current issue of The New England Journal of Medicine (Vol. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after ... It's important to note that, phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ....

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ... Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program ... Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Furthermore, brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP... Moreover, antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream ....

Bloodstream infections are associated with substantial morbidity and mortality. This perspective suggests that, early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non... Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of .... First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer ... Overall Survival with Inavolisib in - The New England Journal of Medicine.

In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo ...